SVC 101
Alternative Names: SNAPvax cancer vaccine - Avidea Technologies; SVC-101Latest Information Update: 20 Dec 2021
At a glance
- Originator Avidea Technologies
- Class Cancer vaccines; Conjugate vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Dec 2021 Avidea Technologies has been acquired by Vaccitech
- 17 Sep 2021 SVC 101 is available for partnering as of 31 Aug 2021. https://www.avideatechnologies.com
- 31 Aug 2021 Preclinical trials in Cancer in USA (IV) as at August 2021 (Avidea Technologies pipeline, August 2021)